The Role of ITGAM in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Clinical Trial

Official title:

TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01230112
• Other study ID #: 09-289
• Status: Completed
• Phase: N/A
• First received: October 27, 2010
• Last updated: July 29, 2013
• Start date: December 2009
• Est. completion date: April 2012

Study information

• Verified date: July 2013
• Source: Northwell Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health

• Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion Criteria:

• History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease

• History of cancer or lymphoma

• Current use of aspirin, prednisone, or NSAID or any immunosuppressant

• Self reported HIV

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Locations

Country	Name	City	State
United States	Feinstein Institute for Medical Research	Manhasset	New York

Sponsors (2)

Lead Sponsor	Collaborator
Northwell Health	National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States,